Good. Awesome. Well, thanks everyone for joining another session here. Excited to be here with the Cytokinetics team of Isaac Ciechanover, CBO, Steve Heitner, CMO, Jeff Lotz, U.S. Sales and Ops VP, and Sung Lee, CFO. Lots to discuss, a lot going on in the HCM space, so maybe we can just get right into it, and it would be great to maybe just start with a brief overview of sort of the quarter and kind of some of your key takeaways now that we are kind of into the aficamten launch.
Sure. First of all, thanks so much for giving us the opportunity to come and speak. It was a great quarter, if you look at it from all metrics. Revenue was up 76% versus Q2, patient dispense greater than 2,800 versus 1,500.
CMI market, a year-over-year growth of 45%. On the regulatory side, we are now approved in five countries, five regions, and Europe is expanding. We have a number of upcoming important events with the sNDA of MAPLE-HCM next week. We have nHCM by the end of the year, the submission. Earlier in 2027, we will have in Europe. On the pipeline side, we released the data of ACACIA-HCM at ESC. We just have completed the main study treatment period for CAMELLIA-HCM in Japan.
All of this great movement forward, and it really puts us in a very strong position.
Yeah. No, totally. I think there's a pretty strong appreciation that the aficamten launch is going really well. I think one of the most interesting metrics is you're already nearing new-to-brand share sort of preference, or new start preference. I guess maybe what's really driving that, and what have you seen so far in sort of the launch in terms of the pushes and pulls here, and what's really having docs gravitate towards aficamten over CAMZYOS?
We're seeing, obviously, an expansion of prescribers and then increased productivity
In each one of those trialists that start up. The primary drivers are a differentiated clinical profile, which directly translates into a REMS that is, I guess, less burdensome on a comparative basis. All the things that you would expect to hear, rapidity with efficacy, flexible dosing and monitoring-
Shorter half-life on the safety side, no excursions in SEQUOIA-HCM.
Which translates into a REMS where we just monitor safety at the current dose.
Yeah.
It doesn't have some of the other complicated or burdensome measures that the competition has.
Yeah, makes sense. Are you seeing docs sort of take advantage of that flexibility as it relates to dosing, the monitoring echoes? Are they sort of
Yeah.
Fitting it into their workflow in an easier way?
Yeah. The titration and monitoring window, two to eight weeks, we see them using the full window.
There's some that are very aggressive, and it's usually patient-dependent, and they'll try to push the dose every two.
But I think on average right now, we're seeing people in that four to six weeks.
Some people just put it into the same workflow that they're accustomed to and monitor at week four, but we are seeing use of the full window.
Yeah. I think one of the other, especially as it relates to expanding the prescriber breadth of this class, is that you already have a meaningful number of prescribers in these low-volume or CMI-naive patients or prescribers. Maybe kind of just expand on that dynamic, how you see that evolving over time, and who are these docs? Are they people who wanted to use this class but just didn't want to use CAMZYOS, or is it just part of this broader momentum of the community getting more comfortable with these agents?
Yeah. So I would say it's a couple things. It's definitely the early innings of a space that's developing, right? The prescriber base has been growing for four or five years now, and it certainly has accelerated a bit with the launch of MYQORZO. The naive group is largely a group of community cardiologists that don't have the staff-
That you would see at a COE or at an established HCM clinic. So they stayed off on the sidelines with the CAMZYOS launch.
With the differentiation in the clinical profile, and again, translating into a REMS with a flexible window and no need for DDI counseling-
and DDI coaching on a monthly basis, no need to thread a needle on monitoring and prescriptions.
in the 30 - 35 days, it creates enough flexibility that they're willing to try.
There's probably two other components, too, with that group. One is the MAPLE-HCM study is definitely a study that gets people to move quicker.
In the naive group, it's caused people to try a CMI, or at least they're more inclined to give it a shot. Lastly, with the release and readout of ACACIA-HCM, some of these physicians are thinking ahead and saying, "Well, if there's an approved agent for nHCM in the future, maybe I should start thinking about managing these patients myself.
I'm not referring all my HCM patients to someone else.
Yeah. Makes sense. Are you seeing these docs write multiple scripts and become repeat prescribers, or is it kind of more one-off?
Yeah. On average right now, productivity across our prescriber group is about four patients per doc, and that's been growing. In the CMI, like the concentrated high CMI user group, it's seven.
In the naive group, we've seen them move on average from one to two.
They're still in the onesie-twosies, like we like to call them.
Yeah.
Dabbling, but definitely seeing productivity incrementally increasing.
Yeah. Then I guess as it just relates to broader prescriber breadth here, like, how many docs are REMS certified? What percent are prescribing today? What is sort of the timeline to kind of that expanding further in terms of capturing all of them?
Yeah. There's an interesting dynamic with REMS certification. Not everybody that REMS certifies is going to write.
It is based on the dynamic of a practice.
In a lot of the clinics, you will have a decision-maker, and then you will have the writers. You may have a cardiologist that leads a lot of the decisions on which agent to use or how to treat a patient, but then the mid-levels do the writing.
Yeah.
All three of those would end up being a certified HCP, but not necessarily show up as a prescriber. When we look at our REMS-certified HCPs, there are over 3,000 of them now. Two-thirds of them are either writing or affiliated to a writer in the same clinic, and then a third of them are not, and that is an opportunity. We add HCPs to the REMS every week.
It is one of those things where we are sort of always catching up.
To those certified writers as patients present themselves in their clinics.
Yeah. Makes sense. So, it seems like a lot of the underlying fundamentals are going really strong here. Are there really any rate limiters, and what does access look like? Has that been a rate limiter at all? Just curious.
Yeah. So far, no. Our access has been improving. Of course, all the payers now have new-to-market blocks.
I think 10, 15 years ago, it was maybe one or two, and now everybody uses that mechanism.
Yeah.
Right? But we have seen on the Medicare side, 90% of the lives covered at parity to CAMZYOS. Then on the commercial side, we are at 60% coverage.
Up from 50 a quarter ago, it continues to improve. We still have a few plans that have the new-to-market blocks in place.
We expect that to continue to improve as we go to 2027.
Yeah, makes sense. I mean, I think one of the pushbacks that I hear in sort of this launch is a view that CAMZYOS is maybe like a little bit more potent, where patients can kind of stay at five milligrams. They do not need to titrate up, whereas Afi maybe you do. I mean, just curious if you guys have a perspective there, and sort of what have you seen in the real world as it relates to efficacy, safety, and like how patients are kind of being titrated up as they need to?
I'll take that. I think I'll start out by saying in the real world, what we've seen is actually quite similar to what was seen when you look at the data that came out of EXPLORER and translating that to the real world with mavacamten. What we've seen is that in the real world, about 80% of prescriptions are in the maintenance phase.
At 5-10 milligrams. So the lower side of what we're seeing. The dose distribution has shifted to the left.
But what that means for aficamten in practice really is that if a patient shows up at a physician's office and they get started on aficamten 5 milligrams and that's all they need, the very next visit is going to be their maintenance visit.
They go, they get one echo, and then they move to maintenance every six months as it stands in the REMS.
Now, this potency claim really is, I do not know if you want to talk to what mavacamten has been from the up and down titration perspective.
You mean in excursions or?
Yeah.
Yeah.
Well, I mean, I will carry on. So in essence, what has happened in practice is mavacamten has been saying, "Well, it is more potent, therefore less patients need to be on higher doses." So they end up on 2.5-
And five milligrams. What is not spoken to is the patients that end up on 2.5 milligrams actually have to down titrate, and that implies that they have to get another echo and another monitoring echo. So it is actually quite burdensome.
From a patient perspective to actually end up on the 2.5 milligram dose. I believe that about 40%, 30%-40% of mavacamten prescriptions end up on that maintenance of 2.5 milligrams.
Mm-hmm. Yeah. Makes sense. Yeah, again, it seems like you highlighted the flexibility is really what's gaining traction with aficamten. I know you have had some CAMZYOS switchers. Just curious if you could comment on that dynamic and how that's going to evolve at all, if at all, over time.
Yeah. Switching is not an area of focus for us. It's been pretty consistent through the first three quarters of launch. It's in the mid-single digits. So it's a really small percentage.
Yeah. Okay. So, I think on earnings it was 45% new-to-brand share, 50% in the higher, or nearing 50% in the higher volume prescribers. You seem really confident in your ability to kind of get above 50% by the end of this year. Just curious what is needed to kind of get above that 50%, and then what is the ultimate number here in terms of, is it 75% over time that you're going to get new-to-brand starts? Where do you think that number kind of lands?
Yeah, we haven't really guided, I guess, in terms of what our aspirational share is.
Yeah.
But I'm sure this is definitely a bit of a marathon, not a sprint.
Yeah.
It's a longer-term game. I would expect to see continued share growth. We had rapid share growth in the beginning of our launch.
But that exceeded maybe 30% just in the first couple months.
Yeah.
Every share point from this point on is just a little harder to get, right?
It just comes with adoption. Like I mentioned before, we are adding HCPs to our REMS-certified HCP list every week.
We have accounts that are just getting started, for whatever the reason may be. In some cases, it was waiting for their support staff to adjust workflows to a new type of REMS, right?
In some cases, it is a health system waiting for their own specialty pharmacy to come on board to have access to the product. So we continue to add accounts and add prescribers on a weekly basis.
James, I will just add, we have only been on the market for eight months when we got close to 45% NBRx share, so that is quite an accomplishment.
Simply, we believe this is a function of time. We simply need more quarters on the market to achieve our objectives, and I think it is too early to call a ceiling on market share.
Yeah.
We are focused on execution, and our goal is to get this medicine in the hands of as many patients as possible.
Yeah.
The other aspect, of course, is nHCM.
Yes, and yeah.
I don't think there's anybody who would question that if we were successful in moving forward with the FDA
And getting the label ultimately to have one drug
in the hands of physicians to treat all patients, remove the burden of actually having to have two different REMS programs.
Yeah.
All of that is going to have impact ultimately on.
Totally. Yeah. I definitely want to get to non-obstructive, but maybe one last question, kind of looking at 2027. Maybe this is a question for Sung. I think one of the interesting metrics you reported on earnings is just the overall growth of this class is 3,000 patients a quarter, and it is continuing to grow. You are about to sort of get preferential share within that going into next year. As you kind of look at 2027, are people, and I guess beyond too, modeling this the right way based on those numbers and the dynamics here? Are people being too conservative, too optimistic? Just curious how you think.
Sure
Wall Street is on the model.
Yeah, so without endorsing any estimates out there, we are in growth mode. As I mentioned before, we are still very early in the launch, yet I think it is well understood from a demand perspective, from a revenue perspective, we are ahead of where our competitor was same point in time.
As we look to next year, the focus will remain on execution. Isaac mentioned before, we have this potential doubling of opportunity in nHCM. This will be a very important thesis for our company in the coming years, as well as oHCM.
Yeah. Makes sense. Just on that point with non-obstructive, obviously, I think people are super interested in that. Just curious, as we think about that label expansion, should we be expecting any changes to the label, the REMS? What is your kind of perspective going into that potential expansion?
For MAPLE-HCM?
For non-obstructive, just as that expands.
To go.
Well, I mean, obviously, we need to get the approval first. But assuming things go according to what we want, there will be label expansion. It is a new indication.
Yeah.
Non-obstructive HCM is considered different enough. The REMS and prescribing information, so I will just take a step back and remind you how we got the current label for obstructive HCM, and that is the rubric that we are hoping to implement for the non-obstructive program. For obstructive, we used the SEQUOIA-HCM study as the evidence, but we also used data from FOREST-HCM.
FOREST-HCM is where this concept of flexible titration came from. In FOREST-HCM, that is where the six-monthly monitoring came from.
The FDA took the totality of that evidence and then generated the label as we see it and know it now.
For non-obstructive HCM, we are going to be using ACACIA-HCM, which is our body of evidence. 400 patients from the ACACIA study, that is 95% of eligible patients have enrolled in FOREST-HCM. We have gotten a ton of data from them as they have moved through the flexible titration, physician-guided titration schedule of FOREST-HCM. We would certainly like to use that as the platform to actually mirror, if possible, the timing and the thresholds that are in the obstructive to make it as simple as possible for providers.
The only difference being that obviously, non-obstructive HCM, you do not have the LVOT obstruction gradient to use as your metric for titration. It is just based on your ejection fraction.
Mm-hmm. Yeah. Makes sense. I think in the context of some of those data, maybe the one thing that people had a question around coming out of ESC or was new was this non-ejection fraction heart failure dynamic.
Right.
In sort of the titration. That was with ACACIA and kind of like this force sort of algorithm. Maybe just sort of comment on sort of your perspective of that dynamic and sort of what is the right way to think about what that safety sort of dynamic means?
All right. Just to level set, you are referring to the imbalance. There were 12 patients who developed heart failure in ACACIA-HCM during titration, and that was an imbalance as to the three patients on placebo who developed it later on during the study.
When we looked at the same period of time, the titration period during FOREST, we did not see that.
The question was why, and it actually is quite simple. It is because in ACACIA-HCM, the titration algorithm was driven by a computer. There was no input from the treating physician. There was no clinical thought put into whether to titrate a patient or not. So a patient could have come in feeling sick, and the machine would titrate them up. Whereas in FOREST, the physician would see the patient, have a conversation with them, examine them, look at the echocardiogram, just like we would in normal clinical practice, and that risk disappeared, even in the patients who had previously been exposed to placebo.
You can't really say that there was a selection bias or the patients who had an event didn't participate. Therefore, what we're saying is that the implementation of clinical judgment and the ability to skip a titration if the patient isn't feeling up to it made all the difference.
Mm-hmm. Yeah. No, that makes sense. I guess just sort of in the context of safety more broadly, the efficacy data that you've seen in ACACIA-HCM, non-obstructive is maybe a little bit more heterogeneous than obstructive. Do you think CMIs are good candidates for all non-obstructive patients, or are docs maybe going to have to work a little bit harder to find kind of the right patient for one of these drugs, or for aficamten?
I'll actually correct you and say that it wasn't heterogeneous.
The treatment effect was actually remarkably homogenous.
Yeah.
If you look at the Forest plot, there were no pre-specified subgroups that looked like there was a concentration of efficacy. They all had the point estimate to the side of the line that indicated benefit.
Yeah.
The way I would see this being implemented in practice is that because you cannot reliably predict who is going to respond and who isn't, you really have to treat all patients with symptomatic non-obstructive HCM as if they could respond.
The beautiful thing about this drug is that there is a great biomarker as to whether the drug is being efficacious or not, and that's asking the patient how they feel.
I would see it being implemented as in a way a patient shows up with symptoms and non-obstructive HCM, you have a conversation about the risk-benefit, you start them on the low dose, you titrate them to the maximal tolerated dose, and then you say, "When you've been on that dose for a period of time, let's have a conversation as to whether you're feeling better or not. And if you're feeling better, then we continue down this path, and if you're not, then we need to think about some other strategy.
Yeah. Makes sense. I guess, as it relates to the launch, the non-obstructive launch, assuming approval, is the obstructive launch kind of the cadence that we have seen here sort of the best analog for what that may look like, or is it going to be faster, slower? Just curious how we should think about that.
Yeah. We think about it as the same.
A similar cadence. I guess there is a couple considerations. One is in the CMI experience group and certainly the MYQORZO experience writer group, we would expect an acceleration.
But could potentially be offset by the fact that we still have work to do to develop the nHCM market.
There's still disease state education. In contrast to, when we launched, the market had about four years of development by BMS, and they did a tremendous job
Yeah.
Doing that. So we still have that work to do with N.
Yeah. You've talked about the halo effect, which I think totally makes sense and something that resonates very clearly when talking to docs. Do you also expect the obstructive launch to inflect with this approval, or are we already starting to see some of that halo effect pull through?
Yeah. It's hard to quantify any type of halo effect because we don't see nHCM prescriptions, right?
Yeah.
There's no way to tell whether you also have payers who should be limiting
Yeah.
The ability for an nHCM patient to get that therapy. The only thing I would say is that, anecdotally, we do hear about people who are thinking about the future.
It potentially is starting to have them prepare in a certain way. Maybe there's a bias on selection now.
It's probably a little early to-
Yeah
say that. Yeah.
Yeah.
I think from a mechanical standpoint, when you have a practice, and we have an indication for both non-obstructive and obstructive, it just seems logical that the non-obstructive will pull all potential obstructive patients into the same rubric.
Yeah. There's no doubt that the research says there's a halo effect come the approval.
Yeah.
But I just think to say that it's already starting to happen would probably be too early.
Yeah. No, that totally makes sense. And just last on sort of this non-obstructive launch, from a payer perspective, do you get a lot of leverage in sort of like already your interactions within the obstructive side? Is there another sort of big lag to get non-obstructive approved, or should that be much quicker than even what we've seen with obstructive?
Yeah. So those payers are definitely looking ahead to that event. To say that it would be quicker, I wouldn't want to say that with certainty, but we're definitely planning for access to improve as part of that approval.
Yeah. Makes sense. All right. Maybe in the last five minutes here, we can talk about just the broader competitive landscape, because I think that's a very topical one for folks. Obviously, Edgewise has had their recent updates in terms of a trial design, their mechanism reveal. Just sort of curious your perspectives on kind of the updates and how you think about them.
Sure. I mean, I can start. Look, first of all, we congratulate them.
I think any drugs that can help patients, we support, but there's certain realities.
We're not standing still.
The ability for them or for any other competitor to go into a phase III study and then ultimately get approved, we're going to be years in the market. Four years from now, we see ourselves continuing this trajectory and being the leaders in this space. Also, we're collecting real-world data. We talked a little bit about FOREST-HCM. We now have another study called ASPEN.
You've seen it with CAMZYOS, with experience, and there's really no substitute for real-world experience.
Yeah.
You can say what you want, but ultimately, the agency wants to see that data. That is going to affect our ability, and we hope to change our REMS and how physicians use the drug. From that perspective, we feel really good. The other aspect to it is, look, you can go to the agency, and as long as you have a reasonable protocol, you can move forward and do it at your own risk. That is very different than saying that the agency has approved, and now you have a label that somehow removes certain requirements.
I mean, you know our own experience as it relates to REMS. When you get to the Division of Risk Management as you are negotiating the label four years from now, then we will see ultimately how that goes. All of that, per se, again, I think it is a little premature. Our focus really is about making sure that we can drive our launch, we can continue to We will be the first drug, hopefully, to be approved in HCM. We showed with the ACACIA-HCM study itself that is not an easy feat to do.
Yeah.
All of that gives us a lot of confidence about where we will be, and we will continue to drive shareholder value and invest in our pipeline along the way. Again, I will let the other companies focus on what they need to do because the bar is pretty high.
Mm-hmm. Yeah. No, definitely. Yeah, I think there was an interesting comment you made. Designing a phase III with the cardio-renal division is very different than who is deciding the REMS. Is that the right sort of take there?
Yeah. Look, the agency is about mitigating risk at the end of the day. I know you are a new therapy, and you Look, we can only talk about precedent.
Yeah.
From the CMI market, there are now two approved, and they both required it, and the agency asked for both.
Yeah.
I mean, we will see what happens, but we will only see years from now. That, I think, is non-controversial.
Yeah.
But the reality of it is I do not see them changing their practice.
Yeah. I think you mentioned this ASPEN study. I think it is really interesting. Maybe just talk a little bit about exactly what that study is designed to show, and is that really a design study specifically for going to the agency about easing a REMS?
Sure.
Yeah, that is probably the main strategy behind that study. Essentially, it is looking at the real-world safety and efficacy of aficamten use in obstructive HCM.
The intent is to collect a broader group of patients that are not necessarily clinical trial patients and follow them for a longer period of time from an exposure perspective and generate data that will furnish the several thousands of patient years necessary that is part of the precedent for unwinding a REMS program.
There are several components of that strategy with ASPEN and FOREST-HCM just being two of them.
Yeah. Would one of the ideas maybe be, you do not need to do echoes at five and 10 milligrams or something, and that is like in a community setting, a doc could just not have to worry about using a REMS, and then if they need more, they can get referred to a community center. Just curious how you think it is going to evolve in practice as it relates to this REMS easing.
Well, I mean, I think the first thing to bear in mind is that echoes are cardiologists' friends.
They like doing them on patients. It is not like they want to divorce themselves entirely of having to get an echo on a patient. It is the fixed nature of the REMS program that patients and cardiologists hate.
We have built that into our current REMS program so that patients can have tremendous flexibility as to when to get those echoes.
Titrating according to whether it is your clinical acumen or whatever you use to titrate is, I guess, cute, but it is not necessarily what is going to happen in the real world.
You have to put yourself in the shoes of a treating cardiologist. When they start a medication, they are going to want to know whether it is working.
Yeah. And the best way to do that is with an echo.
Yeah.
Yeah. Fair enough. I know we are just like 20 seconds over, but maybe last question, Sung. Just in terms of the balance sheet, runway, where should our heads be at in terms of your financial position?
Sure. We are in a very strong financial position. We ended the last quarter with $1.6 billion in cash and investments. This will allow us to fund the launch, not only continue in the U.S., but also launches in Europe that are coming up. Also, to advance our pipeline, we have some important programs, late stage omecamtiv mecarbil, ulacamten phase II. Those are very important programs for us to continue to advance. Now, of course, our future depends a lot in the near term on the trajectory of oHCM.
But there are scenarios where, based on our current cash balance and our internal projections, we could be cash flow positive in two to 2.5 years.
Mm-hmm. Okay. That is really helpful. A lot more we could talk about, but thanks, guys, for being here, and thanks everyone for listening in.
Thank you
Thank you.
Thanks for having us.